Details

Autor(en) / Beteiligte

• Rommer, P. S.
• Dudesek, A.
• Stüve, O.
• Zettl, U.K.

Titel

Monoclonal antibodies in treatment of multiple sclerosis

Ist Teil von

• Clinical and experimental immunology, 2014-03, Vol.175 (3), p.373-384

Ort / Verlag

England: Oxford University Press

Erscheinungsjahr

2014

Quelle

MEDLINE

Beschreibungen/Notizen

• Summary Monoclonal antibodies (mAbs) are used as therapeutics in a number of disciplines in medicine, such as oncology, rheumatology, gastroenterology, dermatology and transplant rejection prevention. Since the introduction and reintroduction of the anti‐alpha4‐integrin mAb natalizumab in 2004 and 2006, mAbs have gained relevance in the treatment of multiple sclerosis (MS). At present, numerous mAbs have been tested in clinical trials in relapsing–remitting MS, and in progressive forms of MS. One of the agents that might soon be approved for very active forms of relapsing–remitting MS is alemtuzumab, a humanized mAb against CD52. This review provides insights into clinical studies with the mAbs natalizumab, alemtuzumab, daclizumab, rituximab, ocrelizumab and ofatumumab.